A Case of XIAP Deficiency Successfully Managed with Tadekinig Alfa (rhIL-18BP)

J Clin Immunol. 2022 May;42(4):901-903. doi: 10.1007/s10875-022-01236-2. Epub 2022 Mar 19.

Authors

Ashley V Geerlinks¹, Andrea M Dvorak²; XIAP Deficiency Treatment Consortium

Collaborators

XIAP Deficiency Treatment Consortium:
Michael B Jordan, Eduardo J Schiffrin, Edward M Behrens, Rebecca Marsh

Affiliations

¹ Children's Hospital London Health Sciences Centre, London, ON, Canada. ashley.geerlinks@lhsc.on.ca.
² SUNY Upstate Medical Center, Syracuse, NY, USA.

PMID: 35304666
DOI: 10.1007/s10875-022-01236-2

No abstract available

Keywords: IL-18; Immune dysregulation; Tadekinig alfa; XIAP deficiency.

Publication types

Case Reports
Letter

MeSH terms

Genetic Diseases, X-Linked*
Humans
Immunosuppressive Agents
Lymphoproliferative Disorders*
X-Linked Inhibitor of Apoptosis Protein

Substances

Immunosuppressive Agents
X-Linked Inhibitor of Apoptosis Protein
XIAP protein, human

Supplementary concepts

Lymphoproliferative Syndrome, X-Linked, 2